Subscribe to CarissaRaman.com Subscribe to CarissaRaman.com's comments

Archive for the ‘Amsterdam’ category

Article source: http://www.ed.nl/economie/dejavu-events-uit-eindhoven-kleurt-amsterdam-oranje~a7eb2c46/

Having trouble signing in?

Contact Customer Support at
customer.service@haymarket.com
or check our frequently asked questions about signing in to the site.

Article source: http://www.citmagazine.com/article/1430695/hyatt-hotels-debuts-amsterdam

ING PROFILE

ING is a global financial institution with a strong European base, offering banking services through its operating company ING Bank. The purpose of ING Bank is empowering people to stay a step ahead in life and in business. ING Bank’s 52,000 employees offer retail and wholesale banking services to customers in over 40 countries.

ING Group shares are listed on the exchanges of Amsterdam (INGA AS, INGA.AS), Brussels and on the New York Stock Exchange (ADRs: ING US, ING.N).

Sustainability forms an integral part of ING’s strategy, which is evidenced by the number one position among 395 banks ranked by Sustainalytics. ING Group shares are being included in the FTSE4Good index and in the Dow Jones Sustainability Index (Europe and World) where ING is among the leaders in the Banks industry group.  

 

IMPORTANT LEGAL INFORMATION

Elements of this press release contain or may contain information about ING Groep N.V. and/ or ING Bank N.V. within the meaning of Article 7(1) to (4) of EU Regulation No 596/ 2014.

Projects may be subject to regulatory approvals. Insofar as they could have an impact in Belgium, all projects described are proposed intentions of the bank. No formal decisions will be taken until the information and consultation phases with the Work Council have been properly finalised.

Certain of the statements contained herein are not historical facts, including, without limitation, certain statements made of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Actual results, performance or events may differ materially from those in such statements due to a number of factors, including, without limitation: (1) changes in general economic conditions, in particular economic conditions in ING’s core markets, (2) changes in performance of financial markets, including developing markets, (3) potential consequences of European Union countries leaving the European Union or a break-up of the euro, (4) changes in the availability of, and costs associated with, sources of liquidity such as interbank funding, as well as conditions in the credit and capital markets generally, including changes in borrower and counterparty creditworthiness, (5) changes affecting interest rate levels, (6) changes affecting currency exchange rates, (7) changes in investor and customer behaviour, (8) changes in general competitive factors, (9) changes in laws and regulations and the interpretation and application thereof, (10) geopolitical risks and policies and actions of governmental and regulatory authorities, (11) changes in standards and interpretations under International Financial Reporting Standards (IFRS) and the application thereof, (12) conclusions with regard to purchase accounting assumptions and methodologies, and other changes in accounting assumptions and methodologies including changes in valuation of issued securities and credit market exposure, (13) changes in ownership that could affect the future availability to us of net operating loss, net capital and built-in loss carry forwards, (14) changes in credit ratings, (15) the outcome of current and future legal and regulatory proceedings, (16) ING’s ability to achieve its strategy, including projected operational synergies and cost-saving programmes and (17) the other risks and uncertainties detailed in the most recent annual report of ING Groep N.V. (including the Risk Factors contained therein) and ING’s more recent disclosures, including press releases, which are available on www.ING.com.  Many of those factors are beyond ING’s control.

Any forward looking statements made by or on behalf of ING speak only as of the date they are made, and ING assumes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information or for any other reason.

This document does not constitute an offer to sell, or a solicitation of an offer to purchase, any securities in the United States or any other jurisdiction.

Article source: https://globenewswire.com/news-release/2017/04/25/971057/0/en/ING-to-participate-in-Bank-of-Beijing-share-offering.html

Early Sunday morning: We confess to initially being less awake than the statue at the entrance to the Amsterdam convention center. Strong coffee and strong messages about hepatitis elimination quickly brought us to life.

The Sunday edition of The New York Times often includes a short feature in which a prominent person is asked to describe how he or she likes to spend an idle Sunday. Common activities are brunch, museums, outdoor activities, etc.

This came to mind yesterday as we watched more than 160 people gather for one of the final sessions of the fifty-second International Liver Congress (ILC). Whoever would have expected so many prominent people to pass on a leisurely Sunday morning in Amsterdam, after four long days of events, in favor of an 8.30 a.m. gathering titled “Elimination of hepatitis B and C in the EU: challenges and opportunities”?

The event emphasized the tremendous potential of direct-acting antiviral (DAA) treatment regimens to reduce HCV prevalence and incidence in PWID, as well as the programmatic, political and structural barriers that must be overcome to make real progress on the ground.

This session represented only one of many ways in which the European Association for the Study of the Liver (EASL) helped to foster the dialogue about public health dimensions of viral hepatitis at this year’s ILC. (Disclosure: the first author is a board member of EASL’s recently launched International Liver Foundation.)

For us, one of the highlights of the conference was a 19 April workshop jointly convened by EASL and the International Network on Hepatitis in Substance Users (INHSU). A broad range of participants discussed efforts to eliminate hepatitis C virus (HCV) in people who inject drugs (PWID) from multiple perspectives. The event emphasized the tremendous potential of direct-acting antiviral (DAA) treatment regimens to reduce HCV prevalence and incidence in PWID, as well as the programmatic, political and structural barriers that must be overcome to make real progress on the ground.

The ILC programme also included a well-attended World Health Organization (WHO) symposium on “Hepatologists as key partners in meeting the elimination goals of the WHO hepatitis strategy”. And at an abstract-driven session titled, “Public health issues in hepatology”, valuable learnings were shared from two countries with national HCV elimination programmes, Georgia and Iceland, as well as from experiences in key populations including migrants, prison inmates and PWID.

We applaud the ILC’s organisers for recognising that non-biomedical experts include not only a range of health service providers and public health practitioners but also liver patients.

Multidisciplinary approaches to liver disease were prominent at this ILC. We mean this both in the sense that the programme brought hepatologists and other types of physicians into dialogue about multidisciplinary clinical care, and also in the sense that it provided physicians and other experts with valuable opportunities to learn from each other.

It is exciting to see public health perspectives thoughtfully integrated into such a prestigious biomedical conference. And we applaud the ILC’s organisers for recognising that non-biomedical experts include not only a range of health service providers and public health practitioners but also liver patients.

Delegates from liver patient groups bring perspectives that the rest of us need to hear. Tatjana Reic, President of the European Liver Patients Association, aptly demonstrated this at the Sunday morning event on HBV/HCV elimination in the EU. Instead of referring to PWID as a “hard-to-reach” population, she remarked during her presentation, why not refer to them as an “easy-to-ignore” population?

Indeed.

We look forward to the further cross-pollination of diverse ways of thinking within EASL and at future editions of ILC.


Hepatology, Medicine and Policy is now accepting submissions on this and related issues. For more information, visit: www.hmap.biomedcentral.com.

Article source: http://blogs.biomedcentral.com/on-health/2017/04/25/elimination-at-ilc2017-make-mine-a-double-espresso-that-is/

Our favorites

Article source: http://www.deephouseamsterdam.com/movement-sonus-festival-join-forces-summer-event/

‘)})();
//–

Aviation Daily

WASHINGTON—The Dutch Safety Board (DSB) is calling on the Dutch Ministry of Infrastructure and the Environment to determine who in the government should have “final responsibility” for the safety of air traffic at and around Amsterdam Airport Schiphol.

The request is one of eight recommendations included in a final report capping a yearlong investigation into an increase in runway incursions and other on-airport incidents since 2014.

While the DSB said it had found “no evidence to suggest that safety at Schiphol is inadequate,” officials did find many opportunities for improvement. Those include the need for a central authority with final responsibility. “The ministry has no overall picture of aviation safety at and around Schiphol, nor is it able to determine whether the main safety objectives are being achieved,” the DSB said. “In addition, the Human Environment and Transport Inspectorate lacks the knowledge and resources required to maintain effective in-depth oversight of the parties operating at Schiphol.”

The DSB launched the probe in March 2016, after seeing “a series of incidents, some of which occurred more than once” at the airport starting in 2014, and coincident with an increase in traffic. The agency’s goal was to determine if the problems were due to multiple root problems, including layout, location and how operators are using the facility.

“Schiphol is a complex airport, both in terms of its infrastructure and in terms of how air traffic is handled,” the DSB said. “This complexity entails certain risks for air traffic. Schiphol’s rapid growth is increasing that complexity further.”

Events recorded in 2014–16 include a pushback incident in November 2014; a clearance and takeoff of an Airbus A320 from a closed runway in June 2015; and a runway incursion in February 2016.

The DSB said factors behind the incidents include high workload and “capacity shortages” for air traffic controllers, and “not enough room to park aircraft.” Additional risks include traffic crossing the takeoff and landing runways; deviations from procedures to handle the traffic; and a large number of daily runway configuration changes—many of which are the result of “noise preferential flight operations” for communities. “All of this indicates that Schiphol is approaching the limits of its ability to handle air traffic safely within the current operational concept,” the DSB said.

Of concern to the DSB is that no single party takes responsibility for the integral safety of air traffic at and around the airport. While the Dutch government is ultimately responsible for safety at the airport, the DSB said that role has been delegated to “parties” that have not delivered “comprehensive, collective safety guarantees.”

Several of the recommendations are focused on the airport operator, Schiphol Group, and the nongovernmental air navigation services provider, Luchtverkeersleiding Nederland, or LVNL. Included are calls to develop “future-proofed” operational concepts for the airport, potentially including reducing runway configuration changes and complexity of the layout; and developing a “shared vision” on safety at Amsterdam Schiphol, including targets to be achieved.

The DSB is asking the Netherlands government to “flesh out the role of the party with final responsibility for safety at and around Schiphol,” in addition to actively monitoring safety; performing trend analyses; and carrying out “comprehensive assessments” of the safety impacts of potential changes due to the recommendations.

“This investigation makes it clear that further growth of Schiphol will require more than marginal adjustments to the existing policy,” said the DSB. “Indeed, this calls for a fundamental debate on the future of aviation in the Netherlands and on the options and limitations regarding Schiphol’s further growth.”

Please Log In or Register to post comments.


Commercial Aviation: Market Briefing

A subscription to Aviation Daily is required to access these stories.

 

 

Subscribe

Log In



Advertise with Us


Daily analysis on technology advances impacting the global aviation, aerospace defense industries.


PISCES





Sponsored Introduction Continue on to (or wait seconds) ×

Article source: http://aviationweek.com/awincommercial/who-charge-safety-amsterdam-schiphol

April 22, 2017, Amsterdam, The Netherlands: Results of the SARAH trial presented today demonstrate that SIRT resulted in median overall survival (OS) of 8.0 months compared to 9.9 months with sorafenib (p=0.179), in patients with locally advanced and inoperable hepatocellular carcinoma (HCC). The trial, presented at The International Liver Congress™ 2017 in Amsterdam, The Netherlands, further demonstrated that the cumulative incidence of radiologic progression in the liver as the first event was significantly lower in the SIRT group compared to the sorafenib group (p=0.014), and the response rate was significantly higher in the SIRT group compared to the sorafenib group (19.0% vs 11.6%, p=0.042). Both the side-effect profile and quality of life scores were significantly better over time in the SIRT group compared to the sorafenib group (p=0.005).

Liver cancer, or HCC, is the second most common cause of cancer-related deaths worldwide.1,2 HCC represents more than 90% of primary liver cancers and is a major global health problem.3 The prognosis for patients with advanced liver cancer is poor,2 and the multikinase inhibitor, sorafenib, is the only approved first-line systemic treatment.3 If patients are not tolerant or have contraindications for sorafenib therapy, there is currently no standard of care and patients lack effective treatment options.3 SIRT with yttrium-90 (Y-90) resin microspheres has shown promising anti-tumour results with a safe profile; further trials are needed to establish this treatment as a viable option for patients.3

“Patients with advanced or inoperable hepatocellular carcinoma have a poor prognosis, often with underlying cirrhosis, and the treatment option currently available, sorafenib, has a high level of toxicity. As cohort studies have demonstrated the efficacy of SIRT with Y-90 resin microspheres, we set out to compare the efficacy of this treatment versus the current standard of care,” said Prof Valérie Vilgrain, Hôpital Beaujon Service de Radiologie, Paris, France, and lead author of the study. “While SIRT demonstrated significantly reduced side effects, better quality of life, higher response rates and more effectively controlled tumour progression in the liver, the overall survival of patients was not higher than in the sorafenib group. Nonetheless, this study provides evidence that SIRT may be a better-tolerated alternative for managing this complex and difficult-to-treat disease, deserving further evaluation.”

The SARAH trial was a randomised, controlled, open-label, multicentre investigator initiated Phase 3 trial. Patients with locally advanced or inoperable HCC, who did not respond to other treatments or had two failed rounds of transarterial chemoembolisation, were randomised to SIRT with Y-90 resin microspheres, or oral sorafenib 400 mg twice daily. The primary endpoint of the study was OS and secondary endpoints included progression-free survival (PFS), time to radiological progression at any site and in the liver as the first event, tumour response, quality of life, and safety and toxicity.

There were 459 patients from 25 French clinical centres included in the study, 237 of whom received SIRT. Median PFS was 4.1 months and 3.7 months in the SIRT and sorafenib groups, respectively (p=0.765). Cumulative incidence of radiological progression at any site did not differ in either group (p=0.256). Overall, there were 1,297 and 2,837 treatment-related adverse events (AEs) including 230 and 411 grade ?3, in the SIRT and sorafenib groups, respectively. The number of patients with at least one treatment-related adverse event was 173 (76.5%) and 203 (94.0%), (p

“The SARAH trial is the first reported randomised controlled trial evaluating the survival benefit of SIRT in locally advanced HCC compared to sorafenib. SIRT was found to be safe, but regrettably the study failed meet the primary endpoint and SIRT did not show an overall survival superior to sorafenib. Further trials are needed to establish this treatment as a viable option for patients,” said Prof Alejandro Forner, BCLC group, Liver Unit, Hospital Clinic Barcelona, Spain and EASL Governing Board Member.

###

Yttrium-90 resin microspheres

Y-90 resin microspheres are miniscule radioactive ‘beads’ that are used in SIRT. They contain the radioactive component yttrium-90. These microspheres are injected in huge quantities into the liver tumours, where they become stuck in the small blood vessels that are in and around the tumours. The microspheres then emit high doses of radiation, which enable doctors to deliver up to 40 times more radiation to the liver tumours than would be possible using standard radiation therapy, all while sparing surrounding healthy tissue.4

About The International Liver Congress™

This annual congress is the biggest event in the EASL calendar, attracting scientific and medical experts from around the world to learn about the latest in liver research. Attending specialists present, share, debate and conclude on the latest science and research in hepatology, working to enhance the treatment and management of liver disease in clinical practice. This year, the congress is expected to attract approximately 10,000 delegates from all corners of the globe. The International Liver Congress™ 2017 will take place from April 19 – 23, at the RAI Amsterdam, Amsterdam, The Netherlands.

About The European Association for the Study of the Liver (EASL)

Since its foundation in 1966, this not-for-profit organisation has grown to over 4,000 members from all over the world, including many of the leading hepatologists in Europe and beyond. EASL is the leading liver association in Europe, having evolved into a major European Association with international influence, with an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in European liver policy.

Contact

For more information, please contact the ILC Press Office at:

  • Email: ILCpressoffice@ruderfinn.co.uk
  • Telephone: +44 (0)7841 009 252

Onsite location reference

Session title: General session III and award ceremony II

Time, date and location of session: 10:00 – 12:00, Saturday 22 April, Hall 5

Presenter: Valérie Vilgrain, France

Abstract: SARAH: a randomised controlled trial comparing efficacy and safety of selective internal radiation therapy (with yttrium-90 microspheres) and sorafenib in patients with locally advanced hepatocellular carcinoma (GS012), 10:00 – 10:15

Author disclosures

Speaker fees: Guerbet, SIRTEX, Supersonic, Toshiba. SIRTEX: Funding of SARAH trial. Guerbet: Study Investigator.

References

1 World Health Organization. Cancer. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/. Last accessed: April 2017.

2 World Health Organization. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Last accessed: April 2017.

3 EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943.

4 Sirtex Medical Liminted. About SIR-Spheres microspheres. Available from: http://www.sirtex.com/us/patients/about-sir-spheres-microspheres/. Last accessed: April 2017.

Article source: https://www.eurekalert.org/pub_releases/2017-04/eaft-sib041217.php

Article source: http://qns.com/story/2017/04/24/family-friendly-new-amsterdam-festival-coming-ridgewoods-historic-onderdonk-house/

Editor’s note: The Anne Frank Museum in Amsterdam, the Netherlands, hosts an invitation-only seminar every spring for teachers and students from multiple countries. This year, the Anne Frank Inspire Academy in San Antonio was selected as one of 12 international schools – and the first U.S. school – to participate.

The 2017 seminar theme was “Youth Voices Today: Exploring Identity through Creative Writing” and focused on the educational value of Anne Frank’s diary, connecting her words to classrooms around the world. In observance of Holocaust Remembrance Day, here are first-person accounts from the Anne Frank Inspiration Academy facilitator, Carrie Ross, and ninth grade student, Zoe Luca.

Photo RNW.org / Creative Commons

The Anne Frank Museum in Amsterdam, the Netherlands.

Thoughts from Carrie Ross (Anne Frank Inspire Academy Facilitator)

I have always wanted to travel internationally. The cultures, ethnic food, and historic locations have piqued my interest for as long as I can remember. Back in college, I was this close to spending a semester abroad in Cork, Ireland. Through a series of unfortunate events, my passport was packed away in a keepsake box, and a few years later I entered the field of education working to open up worlds of possibilities for my students through teaching literature. Looking back now, it seems almost serendipitous that I would find myself drawn to San Antonio’s Anne Frank Inspire Academy and have the chance to dig out that old passport and dust it off.

Article source: https://therivardreport.com/local-delegation-inspired-by-anne-frank-seminar/

Hyatt has announced the opening of Hyatt Regency Amsterdam, the first Hyatt Regency hotel to open in The Netherlands’ dynamic capital city. Hyatt Regency Amsterdam is the third Hyatt-branded hotel in The Netherlands, joining luxury lifestyle hotel Andaz Amsterdam Prinsengracht and select service hotel Hyatt Place Amsterdam Airport.

“The opening of Hyatt Regency Amsterdam marks a significant milestone for the Hyatt Regency brand as it continues to expand its footprint throughout Europe”, said Peter Fulton, group president – Europe, Africa and Middle East, Hyatt. “The hotel is an ideal location for both business and leisure travelers visiting Amsterdam and nicely complements Andaz Amsterdam Prinsengracht and Hyatt Place Amsterdam Airport.”
 
Located in the center of Amsterdam, bordering the energizing East district and right at the heart of Plantage Amsterdam, Hyatt Regency Amsterdam is designed to connect business and leisure travelers to all Amsterdam has to offer. The hotel is nearby some of the city’s best museums, shopping and dining – with easy access to the city’s Metro trains and tram lines, guests can enjoy top sites including Rijksmuseum, Dam Square and Canal Ring. Additionally, the hotel is located less than 10 minutes from Amsterdam RAI Exhibition and Convention Center, and 20 minutes from Amsterdam Airport Schiphol.
 
“At Hyatt Regency Amsterdam, we set the stage for dynamic interactions – from a quick coffee meeting to shared culinary experiences, our guests can come together to socialize, collaborate or celebrate,” said Toni Hinterstoisser, general manager for both Hyatt Regency Amsterdam and Andaz Amsterdam Prinsengracht. “We are confident that the hotel’s spacious accommodations, premier meeting facilities and superior service will provide an authentic experience and one-stop convenience to business and leisure travelers.”
 
Guestrooms
Hyatt Regency Amsterdam has been thoughtfully designed, blending history with a modern-day 24/7 lifestyle. The hotel’s 211 guestrooms, including 15 suites, range in size from 322 square feet (30 square meters) for a standard room to 1,356 square feet (126 square meters) for the Spinoza Suite. Inspired by the invigorating greenery of the hotel’s surroundings that is home to leafy boulevards, the city’s botanical garden and ARTIS Amsterdam Royal Zoo, each guestroom is elegantly decorated with blooming floral and botanical artwork. Flexible furnishings, a generous workspace, large windows, and a striking bathroom with soothing walk-in rain shower complete the guest experience.
 
Authentic Culinary Experiences
Seamlessly flowing out of the lobby, on-site restaurant and bar Mama Makan is the vibrant heart of the hotel’s drinking and dining experience. Evoking the atmosphere of a grand café inspired by the dining and sitting rooms of Jakarta, head chef Paul Verheul and his team take guests and locals on an enticing culinary journey. Bringing together authentic and bold aromas and tastes, Mama Makan is a fusion of traditional Dutch café fare and Indonesian specialties that make a great start or end to the day.
 
The bar is an extension of this captivating space, mixing up daring cocktails inspired by well-travelled spices, herbs and plants. This is also the place for a freshly brewed Javanese-style coffee or an ice-cold drink. When weather permits, the Mama Makan experience will be extended to the hotel terrace, where food and drinks can be enjoyed with the Dutch summer breeze.??
The hotel’s 24-hour café-style market offers one-stop experience for guests to eat and drink whenever and wherever they would like. The market provides a wide selection of refreshing beverages along with delicious homemade pastries and bakery items.??
Event Venues
Boosting more than 5,565 square feet (517 square meters) of flexible meeting and event facilities, Hyatt Regency Amsterdam provides cleverly designed spaces with abundant natural daylight and top-of-the-line audiovisual equipment that can cater all occasions – meetings to conferences, weddings to social events.
 
The hotel’s main event venue is the 2,055-square-foot (191-square-meter) ballroom with eye catching oak wood flooring and floor-to-ceiling windows that overlook the Singelgracht canal. The ballroom is accessible by a separate entrance and is unrivalled in versatility – from seminars to weddings and festive gala dinners, the modern design of the room offers endless opportunities for customizable layouts. The inviting, adjacent foyer is ideal for coffee breaks, breakout sessions or to lounge and connect with others.
 
For smaller groups, Hyatt Regency Amsterdam offers three individual event rooms that can be used individually or can be connected. Sophisticated by design, these meeting rooms provide ample space and flexibility for engaging meetings of any sort.
 
Health and Wellness
Hyatt Regency Amsterdam provides guests with various options to refresh and re-energize, including a 24-hour fully equipped fitness center and sauna. Additionally, guests can enjoy a variety of nearby jogging trails for a run through the city or the nearby Oosterpark.

Submit to DiggSubmit to DiggSubmit to FacebookSubmit to FacebookSubmit to Google PlusSubmit to Google PlusSubmit to StumbleuponSubmit to StumbleuponSubmit to TwitterSubmit to TwitterSubmit to LinkedInSubmit to LinkedIn

Article source: https://www.incentivetravel.co.uk/hotel/38935-hyatt-regency-amsterdam-marks-the-debut-of-hyatt-regency-brand-in-the-netherlands